Large‐scale screens performed in KRAS‐mutant lung and colorectal cancer have shown cyclin dependent kinase 1 (CDK1), TBK1 and GATA2 to be possible synthetic dose lethal partners (Barbie et al., 2009; Costa‐Cabral et al., 2016; Kumar et al., 2012), and this may be therapeutically exploitable in the small fraction of melanoma harbouring an activating KRAS mutation. This evidence concerns the gene CDK1 and melanoma.